Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral HRS-5346 in Adult Patients With Elevated Lipoprotein(a) and High Risk of Cardiovascular Events
NCT07767513Phase 2Not yet recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Sep 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MK-7262 in lipoprotein disorder (2 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoint: Percentage Change in Lipoprotein(a) Levels at 12 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
MK-7262
03
Conditions
lipoprotein disorder
Beyond the preview
Go deeper on NCT07767513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07767513.